Clinical experience with the MEVION S250-FIT™ across adult and pediatric care
Upright proton therapy is entering a new phase of clinical practice.
With two MEVION S250-FIT™ systems now treating patients, clinical experience is demonstrating the versatility of upright proton therapy across adult and pediatric populations, with anatomical targets extending from the brain and head and neck to the chest and pelvis.
For Mevion, this progress reflects a mission that has guided our innovation for decades: giving physicians and their patients access to high-quality, cost-effective proton therapy.

Clinical versatility in practice
Upright treatment is not new to radiation oncology. As early as 1956, one of the first medical linear accelerators incorporated an upright treatment chair. Upright positioning was also used in pioneering proton therapy programs at the Harvard Cyclotron in collaboration with Massachusetts General Hospital, and later at centers such as Institut Curie in Orsay, France. More recently, Northwestern Medicine reported treating 816 patients in upright proton therapy chairs through 2025, across several anatomical regions.
Today, the MEVION S250-FIT combines modern pencil-beam scanning, upright CT imaging, and flexible patient positioning in a compact proton therapy system.
At Stanford Medicine, the first site to treat patients with FIT, a September 2026 clinical snapshot reported nine patients treated across brain, head-and-neck, and chest targets, including pediatric patients and complex re-irradiation cases.
Across the two clinical sites now treating patients, clinical experience extends to pelvic targets, demonstrating an expanding range of anatomical applications. Importantly, these treatments are being integrated into routine radiation oncology workflows. Stanford initially reported treatment sessions of approximately 20 to 30 minutes, with more recent experience presented at PTCOG-NA indicating that sessions can now be completed in as little as 15 minutes.
Expanding treatment opportunities through upright positioning
Upright treatment does not mean every patient is fully seated. The S250-FIT supports different patient positions to accommodate anatomical targets throughout the body:
- Sitting: Brain and head and neck
- Perched: Chest and upper abdomen
- Maximum perched: Lower abdomen and pelvis

Together, these positioning configurations provide the flexibility to address anatomical targets from the brain through the pelvis, supporting a broad range of clinical applications.
Stanford’s pediatric experience is particularly encouraging. Children have been treated both without anesthesia and under general anesthesia, including a 21-month-old patient supported by a specially developed positioning and anesthesia workflow.
Clinical precision remains fundamental
Clinical versatility must be supported by treatment accuracy.
Before treating its first patient, Stanford completed commissioning evaluations across seven anatomical treatment-planning scenarios, including brain, head and neck, breast, pelvis, and craniospinal irradiation. These evaluations met the institution’s predefined acceptance criteria.
A separate independent IROC Houston audit provided an additional assessment of machine output and end-to-end treatment delivery. The commissioning results have been reported in a manuscript currently under peer review.
Together, these evaluations provide an important technical foundation for the continued clinical development of upright proton therapy.
Advancing access to comprehensive proton therapy
The growing experience with the MEVION S250-FIT demonstrates how upright proton therapy can be integrated into a comprehensive radiation oncology program, supporting diverse clinical needs rather than a narrow range of indications.
At Stanford, proton therapy has been incorporated into an existing radiation oncology department, enabling clinicians to select between photon and proton treatment technologies according to each patient’s needs.
Mevion’s mission has always been to expand access to high-quality, cost-effective proton therapy. With the MEVION S250-FIT, that mission is becoming a clinical reality for more cancer centers and the patients they serve.